<DOC>
	<DOCNO>NCT02090101</DOCNO>
	<brief_summary>The metastatic colon cancer major public health problem despite advance chemotherapy ; new drug development treatment pathology . Many study show human colon cancer tumor recognize immune system presence lymphocytic infiltrates tumor bed associate well prognosis . Conversely , effect chemotherapy immune response little studied . Recently importance myeloid suppressor cell ( MDSC ) development colon cancer effect 5- fluorouracil cell population highlight . An accumulation cell blood lymphoid organ tumor progression observe . Moreover , establish death MDSC induce 5-fluorouracil induces activation caspase -1 IL-1beta MDSC . These event promote polarization CD4 T cell intratumoral Th17 lymphocytes . The IL- 17 produced cell exert pro-angiogenic effect induce proliferation endothelial cell express thus limit effect 5- fluorouracil endoglin . In human , also observe chemotherapy use 5- fluorouracil particular LV5FU2 association +/- bevacizumab induces rapid death blood MDSC well activation caspase 1 cell . Thus , production IL - 1 detected serum patient 24 hour administration 5-fluorouracil . Chronic inflammation production interleukin- 1 alter effectiveness anti -tumor immune response facilitate angiogenesis . Many preclinical data suggest role anti -tumor inhibition IL- 1beta , effect combination chemotherapy inhibitor IL - 1beta yet test human . Anakinra drug use human many year treat sign symptom rheumatoid arthritis . In combination methotrexate , patient whose response methotrexate alone satisfactory show interesting result . The dose use clinically 100 mg per day dose propose tested study . In context remember methotrexate chemotherapeutic agent class antimetabolites 5- fluorouracil . RCP drug indicate study originator toxicity similar control arm anakinra arm increase serious infection ( 1.8 % vs 0.7 % ) increase incidence neutropenia ( 2.5 % neutropenia &gt; grade = 1 ) . The main toxicity observe painful inflammatory reaction injection site 70 % patient The investigator believe project could permit validate man preclinical observation show anti-tumor potential combination anakinra 5 fluorouracil .</brief_summary>
	<brief_title>Study Evaluating Influence LV5FU2 Bevacizumab Plus Anakinra Association Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Man woman Age ≥ 18 ≤ 80 year Performance status 0 1 accord ECOG score WHO Patient Metastatic colorectal noncurative progression therapy first line therapy contain 5fluorouracil bevacizumab cancer . Patient low intermediate risk define modified Kohne 's criterion Hepatic metastasis ≥ 1 cm Evaluation Review ( CT chest , abdomen pelvis ) make previous 4 week show presence measurable lesion accord RECIST 1.1 criterion . Indication treatment LV5FU2 + bevacizumab validate Patient whose understanding study good Biological value within follow limit : Bilirubin ≤ 1.5 x upper limit normal ( N ) AST ALT ≤ 5 N Creatinin ≤ 1.5 N creatinin clearance &gt; 60 ml / min Neutrophils ≥ 1.5 . 109 / L Platelets ≥ 100 . 109 / L Hemoglobin ≥ 9 g / dL ( even includable patient transfuse ) . Albumin ≥ 30 g / L Serological hepatitis B , C HIV negative Information give sign informed consent Patient affiliate social security system For woman childbearing age , need effective contraception . Related disease : Other cancer within 5 year prior entry trial concomitant ( except carcinoma situ cervix basal cell carcinoma skin ) . Presence brain metastasis Prognosis estimate survival &lt; 3 month Related treatment : Presence contraindication bevacizumab ( major surgery previous 28 day , risk arterial thrombosis , risk bleeding , deep vein thrombosis without effective anti coagulant treatment unbalanced anticoagulant treatment ) Concomitant systemic Immunotherapy , immunosuppressant , corticosteroid ≥ 1mg/kg hormone therapy : corticosteroid administer chronically , immunosuppressive therapy , biotherapy administer management inflammatory disease ( anti TNF , anti IL6 ... ) Hypersensitivity one compound treatment Latex Hypersensitivity ( cap syringe contain anakinra contains dry natural rubber , derivative latex ) , may cause allergic reaction Peripheral neuropathy grade ≥ 2 History autoimmune disease inflammatory Related patient condition : Participation within 30 day prior study entry another clinical trial experimental molecule . Serious disease unbalance , underlie infection may prevent patient receive treatment Intestinal occlusion sub occlusion history inflammatory bowel disease Pregnancy ( test mandatory inclusion pregnancy ) , lactation lack effective contraception men woman childbearing age Psychiatric disease compromise understanding information accomplishment study Patient guardianship , curatorship judicial protection Unable sign inform consent submit medical followup geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>